Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application

A type 2 diabetes, biomarker technology, applied in the field of risk biomarkers and kits, can solve the problems of expensive, time-consuming and labor-intensive MCI diagnostic methods, and achieve fast detection, low cost, and minimal trauma. Effect

Active Publication Date: 2022-04-01
HUAZHONG UNIV OF SCI & TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide a set of biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their applications in order to overcome the problems of expensive, time-consuming and labor-intensive diagnostic methods for MCI in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application
  • Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application
  • Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] In this embodiment, the level of OPTN in platelets of patients with type 2 diabetes mellitus without MCI (T2DM-nMCI) and patients with type 2 diabetes mellitus accompanied by MCI (T2DM-MCI) is detected. Among them, the diagnosis of MCI in patients with type 2 diabetes was carried out by MMSE analysis.

[0043] Some test results such as figure 1Shown (mean±SEM; ***p<0.001; T2DM-nMCI: n=30; T2DM-MCI: n=34). It can be seen from the figure that the OPTN level in T2DM-MCI platelets was significantly higher than that in T2DM-nMCI group.

Embodiment 2

[0045] Based on previous studies, the inventors proposed a set of biomarkers, including optic nerve protein (OPTN), the ratio of total glycogen synthase kinase-3β to Ser9-phosphorylated glycogen synthase kinase-3β (rGSK-3β) To predict the risk of MCI in patients with type 2 diabetes. And based on the increase of OPTN level and rGSK-3β ratio, a diagnostic method was established, and the diagnostic effect of this method was tested.

[0046] The specific steps of OPTN level detection include:

[0047] a: Collect blood from patients with type 2 diabetes, and then conduct blood tissue separation to extract platelets;

[0048] b: Purify the platelets, then extract and measure the protein concentration in the platelets;

[0049] c: The level of OPTN in platelets of patients with type 2 diabetes mellitus was determined by Western blot assay.

[0050] The specific steps of rGSK-3β level detection include:

[0051] a: Collect blood from patients with type 2 diabetes, and then conduc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of medicine, and discloses a group of biomarkers, kits and applications for predicting the risk of MCI in type 2 diabetes patients. The biomarkers include optic neurin, glycogen synthase kinase-3β, and Ser9-phosphorylated glycogen synthase kinase-3β. The increase of this biomarker can evaluate MCI, which has the characteristics of high accuracy, fast detection speed, low cost, less trauma, and easy acceptance by patients. It provides a scientific and effective early prediction scheme for the occurrence of MCI in patients with type 2 diabetes. The kit can screen for MCI in a wide range of people, and only needs to collect peripheral blood to complete the detection, making it possible to screen for a wide range of elderly population.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a group of biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their applications. Background technique [0002] Alzheimer's disease (AD) is a primary degenerative disease of the central nervous system and the most common type of dementia. The main clinical symptom of AD is slow cognitive decline, including the progressive loss of memory, logical reasoning ability and language function, and finally develops into severe dementia. [0003] At present, there is still a lack of early diagnostic measures for AD, and irreversible brain damage often occurs when patients see a doctor, resulting in poor treatment effects. Therefore, the discovery of early risk factors is of great significance for early diagnosis and intervention. Cognitive impairment in type 2 diabetes mellitus (T2DM) is an independent risk factor for AD. The incidence of T2DM is high and tend...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68G01N33/573
Inventor 王建枝
Owner HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap